Cargando…

Effects of Tegoprazan Versus Esomeprazole on Nighttime Heartburn and Sleep Quality in Gastroesophageal Reflux Disease: A Multicenter Double-blind Randomized Controlled Trial

BACKGROUND/AIMS: Patients with gastroesophageal reflux disease (GERD) frequently experience nighttime heartburn and sleep disturbance. Tegoprazan is a new potassium-competitive acid blocker that can rapidly block acid secretion. This study aims to evaluate the efficacy of tegoprazan compared with es...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Joon Sung, Seo, Seung In, Kang, Sun Hyung, Lee, Sang Kil, Kim, Ah Rong, Park, Hyun Wook, Kim, Bong Tae, Song, Geun Seog
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Neurogastroenterology and Motility 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837551/
https://www.ncbi.nlm.nih.gov/pubmed/36581325
http://dx.doi.org/10.5056/jnm22104
_version_ 1784869105505927168
author Kim, Joon Sung
Seo, Seung In
Kang, Sun Hyung
Lee, Sang Kil
Kim, Ah Rong
Park, Hyun Wook
Kim, Bong Tae
Song, Geun Seog
author_facet Kim, Joon Sung
Seo, Seung In
Kang, Sun Hyung
Lee, Sang Kil
Kim, Ah Rong
Park, Hyun Wook
Kim, Bong Tae
Song, Geun Seog
author_sort Kim, Joon Sung
collection PubMed
description BACKGROUND/AIMS: Patients with gastroesophageal reflux disease (GERD) frequently experience nighttime heartburn and sleep disturbance. Tegoprazan is a new potassium-competitive acid blocker that can rapidly block acid secretion. This study aims to evaluate the efficacy of tegoprazan compared with esomeprazole in relieving nighttime heartburn and sleep disturbances. METHODS: Patients with erosive esophagitis, nighttime heartburn, and sleep disturbances were randomized to receive tegoprazan 50 mg or esomeprazole 40 mg for 2 weeks. The primary endpoint was time to first nighttime heartburn-free interval. The percentage of nighttime heartburn-free days was also compared between the 2 groups. RESULTS: A total of 46 patients were enrolled in this study. Time to the first nighttime heartburn-free interval was shorter with tegoprazan than with esomeprazole but the difference was not statistically significant (1.5 days vs 3 days, P = 0.151). The percentage of nighttime heartburn-free days was higher in the tegoprazan group but the difference was insignificant (57.8% vs 43.1%, P = 0.107). Adverse events occurred in 2 patients. They were mild in severity. CONCLUSIONS: Tegoprazan may induce faster relief of nighttime heartburn symptoms and may improve sleep disorders associated with nighttime heartburn. Further large-scale studies are required to validate our findings.
format Online
Article
Text
id pubmed-9837551
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The Korean Society of Neurogastroenterology and Motility
record_format MEDLINE/PubMed
spelling pubmed-98375512023-01-30 Effects of Tegoprazan Versus Esomeprazole on Nighttime Heartburn and Sleep Quality in Gastroesophageal Reflux Disease: A Multicenter Double-blind Randomized Controlled Trial Kim, Joon Sung Seo, Seung In Kang, Sun Hyung Lee, Sang Kil Kim, Ah Rong Park, Hyun Wook Kim, Bong Tae Song, Geun Seog J Neurogastroenterol Motil Original Article BACKGROUND/AIMS: Patients with gastroesophageal reflux disease (GERD) frequently experience nighttime heartburn and sleep disturbance. Tegoprazan is a new potassium-competitive acid blocker that can rapidly block acid secretion. This study aims to evaluate the efficacy of tegoprazan compared with esomeprazole in relieving nighttime heartburn and sleep disturbances. METHODS: Patients with erosive esophagitis, nighttime heartburn, and sleep disturbances were randomized to receive tegoprazan 50 mg or esomeprazole 40 mg for 2 weeks. The primary endpoint was time to first nighttime heartburn-free interval. The percentage of nighttime heartburn-free days was also compared between the 2 groups. RESULTS: A total of 46 patients were enrolled in this study. Time to the first nighttime heartburn-free interval was shorter with tegoprazan than with esomeprazole but the difference was not statistically significant (1.5 days vs 3 days, P = 0.151). The percentage of nighttime heartburn-free days was higher in the tegoprazan group but the difference was insignificant (57.8% vs 43.1%, P = 0.107). Adverse events occurred in 2 patients. They were mild in severity. CONCLUSIONS: Tegoprazan may induce faster relief of nighttime heartburn symptoms and may improve sleep disorders associated with nighttime heartburn. Further large-scale studies are required to validate our findings. The Korean Society of Neurogastroenterology and Motility 2023-01-30 2023-01-30 /pmc/articles/PMC9837551/ /pubmed/36581325 http://dx.doi.org/10.5056/jnm22104 Text en © 2023 The Korean Society of Neurogastroenterology and Motility https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Kim, Joon Sung
Seo, Seung In
Kang, Sun Hyung
Lee, Sang Kil
Kim, Ah Rong
Park, Hyun Wook
Kim, Bong Tae
Song, Geun Seog
Effects of Tegoprazan Versus Esomeprazole on Nighttime Heartburn and Sleep Quality in Gastroesophageal Reflux Disease: A Multicenter Double-blind Randomized Controlled Trial
title Effects of Tegoprazan Versus Esomeprazole on Nighttime Heartburn and Sleep Quality in Gastroesophageal Reflux Disease: A Multicenter Double-blind Randomized Controlled Trial
title_full Effects of Tegoprazan Versus Esomeprazole on Nighttime Heartburn and Sleep Quality in Gastroesophageal Reflux Disease: A Multicenter Double-blind Randomized Controlled Trial
title_fullStr Effects of Tegoprazan Versus Esomeprazole on Nighttime Heartburn and Sleep Quality in Gastroesophageal Reflux Disease: A Multicenter Double-blind Randomized Controlled Trial
title_full_unstemmed Effects of Tegoprazan Versus Esomeprazole on Nighttime Heartburn and Sleep Quality in Gastroesophageal Reflux Disease: A Multicenter Double-blind Randomized Controlled Trial
title_short Effects of Tegoprazan Versus Esomeprazole on Nighttime Heartburn and Sleep Quality in Gastroesophageal Reflux Disease: A Multicenter Double-blind Randomized Controlled Trial
title_sort effects of tegoprazan versus esomeprazole on nighttime heartburn and sleep quality in gastroesophageal reflux disease: a multicenter double-blind randomized controlled trial
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837551/
https://www.ncbi.nlm.nih.gov/pubmed/36581325
http://dx.doi.org/10.5056/jnm22104
work_keys_str_mv AT kimjoonsung effectsoftegoprazanversusesomeprazoleonnighttimeheartburnandsleepqualityingastroesophagealrefluxdiseaseamulticenterdoubleblindrandomizedcontrolledtrial
AT seoseungin effectsoftegoprazanversusesomeprazoleonnighttimeheartburnandsleepqualityingastroesophagealrefluxdiseaseamulticenterdoubleblindrandomizedcontrolledtrial
AT kangsunhyung effectsoftegoprazanversusesomeprazoleonnighttimeheartburnandsleepqualityingastroesophagealrefluxdiseaseamulticenterdoubleblindrandomizedcontrolledtrial
AT leesangkil effectsoftegoprazanversusesomeprazoleonnighttimeheartburnandsleepqualityingastroesophagealrefluxdiseaseamulticenterdoubleblindrandomizedcontrolledtrial
AT kimahrong effectsoftegoprazanversusesomeprazoleonnighttimeheartburnandsleepqualityingastroesophagealrefluxdiseaseamulticenterdoubleblindrandomizedcontrolledtrial
AT parkhyunwook effectsoftegoprazanversusesomeprazoleonnighttimeheartburnandsleepqualityingastroesophagealrefluxdiseaseamulticenterdoubleblindrandomizedcontrolledtrial
AT kimbongtae effectsoftegoprazanversusesomeprazoleonnighttimeheartburnandsleepqualityingastroesophagealrefluxdiseaseamulticenterdoubleblindrandomizedcontrolledtrial
AT songgeunseog effectsoftegoprazanversusesomeprazoleonnighttimeheartburnandsleepqualityingastroesophagealrefluxdiseaseamulticenterdoubleblindrandomizedcontrolledtrial